Description
Tri-Itra 130 SB (Itraconazole B.P. 130mg) is an innovative antifungal formulation utilizing SUBA (Super Bio-Available) technology, a breakthrough method to improve the absorption and dissolution of poorly soluble drugs. This advanced technology involves a solid dispersion of the drug in a polymer matrix, significantly enhancing its bioavailability compared to the normal crystalline form of itraconazole. As a result, Tri-Itra 130 SB offers superior absorption, making it therapeutically equivalent to a conventional 100 mg capsule of itraconazole.
Itraconazole is a broad-spectrum antifungal agent, effective against a wide range of fungal infections including aspergillosis, cryptococcosis, dermatophytosis, and more. The use of SUBA technology ensures better patient compliance, improved therapeutic outcomes, and superior acceptance compared to other treatments like fluconazole.
Key Features:
- Enhanced bioavailability through SUBA technology.
- Therapeutically equivalent to conventional 100 mg itraconazole capsules.
- Broad-spectrum antifungal activity.
- Better compliance and higher efficacy than fluconazole.
Indications:
- Dermatophyte infections
- Onychomycosis
- Systemic fungal infections
Tri-Itra 130 SB is ideal for patients seeking effective antifungal treatment with improved bioavailability and quicker symptomatic relief.